Sage Journals: Discover world-class research

Abstract

Background:

A major unanswered question in ventilator-associated pneumonia (VAP) management relates to patient response to therapy. We investigated the use of pulmonary cytokines as biomarkers for response to antibiotic therapy for VAP.

Methods:

Prospective, observational pilot study of 12 critically ill trauma patients with VAP using a bronchoscopic bronchoalveolar lavage (BAL) (≥100,000 colony-forming units [cfu]/mL). All patients underwent repeat BAL after three days of adequate antibiotic therapy. Changes in pulmonary effluent interleukin (IL)-8 and tumor necrosis factor (TNF)-α concentrations measured on diagnostic and repeat BAL were evaluated on the basis of the presence of a microbiologic response (<10,000 cfu/mL on repeat BAL).

Results:

Six post-therapy BAL samples showed a microbiologic response. In responders, IL-8 and TNF-α concentrations decreased significantly (1,303 ± 1,150 ng/mL in diagnostic BAL sample vs. 309 ± 448 ng/mL after response; p = 0.08 and 9.9 ± 18.4 ng/mL in diagnostic vs. 0.1 ± 0.1 ng/mL in post-treatment sample; p = 0.06, respectively). In non-responders, IL-8 (449 ± 426 ng/mL vs. 326 ± 319 ng/mL; p = 0.59) and TNF-α (1.2 ± 1.9 ng/mL vs. 0.3 ± 0.3 ng/mL; p = 0.31) did not change significantly. Clinical response measures did not change or increased in responders, whereas these parameters did not change or decreased paradoxically in non-responders.

Conclusion:

This pilot study indicates pulmonary concentrations of IL-8 and TNF-α decrease in microbiologic responders with VAP. Conversely, clinical response parameters were discordant with the microbiologic response. The utility of pulmonary cytokine behavior in evaluating the effectiveness of antibiotic therapy for VAP should be studied further.

Get full access to this article

View all access options for this article.

References

Guidelines for the management of adults with hospital-acquired, ventilator-associated, healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005; 171:388–416.

Kelley

. Cytokines of the lung. Am Rev Respir Dis, 1990; 141:765–788.

Kolsuz

, Erginel

, Alatas

et al. Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia. Respiration, 2003; 70:615–622.

Millo

, Schultz

, Williams

et al. Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med, 2004; 30:68–74.

Dehoux

, Boutten

, Ostinelli

et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med, 1994; 150:710–716.

Boutten

, Dehoux

, Seta

et al. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med, 1996; 153:336–342.

Monton

, Torres

. Lung inflammatory response in pneumonia. Monaldi Arch Chest Dis, 1998; 53:56–63.

Wunderink

. Clinical criteria in the diagnosis of ventilator-associated pneumonia. Chest, 2000; 117:191S–194S.

Croce

, Fabian

, Schurr

et al. Using bronchoalveolar lavage to distinguish nosocomial pneumonia from systemic inflammatory response syndrome: A prospective analysis. J Trauma, 1995; 39:1134–1139.

10.

Miller

, Meredith

, Chang

. Optimal threshold for diagnosis of ventilator-associated pneumonia using bronchoalveolar lavage. J Trauma, 2003; 55:263–267.

11.

Croce

, Fabian

, Mueller

et al. The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures. J Trauma, 2004; 56:931–934.

12.

Bernard

, Artigas

, Brigham

et al. The American–European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med, 1994; 149:818–824.

13.

Croce

, Fabian

, Waddle-Smith

et al. Utility of Gram's stain and efficacy of quantitative cultures for posttraumatic pneumonia: A prospective study. Ann Surg, 1998; 227:743–751.

14.

Kiehl

, Ostermann

, Thomas

et al. Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med, 1998; 26:1194–1199.

15.

Rennard

, Basset

, Lecossier

et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol, 1986; 60:532–538.

16.

Mueller

, Croce

, Boucher

et al. Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. J Trauma, 2007; 63:1329–1337.

17.

Monton

, Torres

, El-Ebiary

et al. Cytokine expression in severe pneumonia: A bronchoalveolar lavage study. Crit Care Med, 1999; 27:1745–1753.

18.

Schütte

, Lohmeyer

, Rosseau

et al. Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J, 1996; 9:1858–1867.

19.

Gibot

, Cravoisy

, Levy

et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med, 2004; 350:451–458.

20.

Dennesen

, van der Ven

, Kessels

et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med, 2001; 163:1371–1375.

21.

Chastre

, Wolff

, Fagon

et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA, 2003; 290:2588–2598.

22.

Croce

, Swanson

, Magnotti

et al. The futility of the clinical pulmonary infection score in trauma patients. J Trauma, 2006; 60:523–527.

23.

El Solh

, Akinnusi

, Wiener-Kronish

et al. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med, 2008; 178:513–519.

24.

Bueno-Cavanillas

, Delgado-Rodriguez

, Lopez-Luque

et al. Influence of nosocomial infection on mortality rate in an intensive care unit. Crit Care Med, 1994; 22:55–60.

25.

Christ-Crain

, Stolz

, Bingisser

et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med, 2006; 174:84–93.

26.

Nobre

, Harbarth

, Graf

et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med, 2008; 177:498–505.

27.

Hochreiter

, Kohler

, Schweiger

et al.

[Antibiotic treatment of surgical intensive care patients: Procalcitonin to guide duration of therapy](Ger)

Anaesthesist, 2008; 57:571–577.

28.

Seligman

, Meisner

, Lisboa

et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care, 2006; 10:R125.

29.

Luyt

, Guerin

, Combes

et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med, 2005; 171:48–53.

30.

Duflo

, Debon

, Monneret

et al. Alveolar and serum procalcitonin: Diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology, 2002; 96:74–79.

Changes in Pulmonary Cytokines during Antibiotic Therapy for Ventilator-Associated Pneumonia

Abstract

Abstract

Background:

Methods:

Results:

Conclusion:

Get full access to this article

References